Yes, I noted that too so really question the person's understanding of the drug development and approval process - no one is disagreeing that there is still a long road ahead. Bit of a pretty basic thing to get wrong in not knowing that Phase IV trials are post-approval real-world data collection studies used for monitoring and potentially exploring other indications.
Ann: Media release - First stroke patient with afamelanotide, page-14
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.53 |
Change
-0.055(0.38%) |
Mkt cap ! $730.1M | |||
| Open | High | Low | Value | Volume |
| $14.61 | $14.99 | $14.40 | $437.1K | 29.99K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 170 | $14.51 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.56 | 18 | 1 |
View Market Depth
| Last trade - 10.19am 10/07/2024 (20 minute delay) ? |
| CUV (ASX) Chart |